Latest Articles

Publication Date
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Defense World

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Defense World

Published: March 2, 2026, 6:50 p.m.
GLP-1–Progestin and Endometrial Cancer Risk - Conexiant

GLP-1–Progestin and Endometrial Cancer Risk Conexiant

Published: March 2, 2026, 5:01 p.m.
Differential expression of c-kit, E-cadherin, and beta-catenin in endometriosis and normal endometrial tissue.

C-kit, E-cadherin and beta-catenin adhesion molecules and proto-oncogenes are thought to be associated with molecular mechanisms related to the invasion, implantation and persistence of ectopic endometrial cells. Comparing the expression …

Published: March 2, 2026, midnight
Role of serum progesterone levels in frozen embryo transfer: an update.

Progesterone plays a pivotal role in implantation and ongoing pregnancy. In the context of assisted reproductive technology (ART), and in particular frozen embryo transfer (FET), increasing evidence suggests that serum …

Published: March 2, 2026, midnight
Meta-analysis of the effect of goserelin acetate implant on improving hormone levels in patients with endometriosis.

Endometriosis is a hormone-related gynecological disease and characterized by the invasion of endometrial cells outside the uterine cavity.

Published: March 1, 2026, midnight
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks

ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon TipRanks

Published: Feb. 27, 2026, 7:47 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer MarketBeat

Published: Feb. 27, 2026, 4:50 p.m.
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - Yahoo Finance

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer Yahoo Finance

Published: Feb. 27, 2026, 4:47 p.m.
ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval - TradingView

ACRV: ACR-368 delivers strong efficacy and safety in serous endometrial cancer, advancing toward approval TradingView

Published: Feb. 27, 2026, 3:34 p.m.
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks

Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data TipRanks

Published: Feb. 27, 2026, 3:24 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!